Karyopharm Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:25K0 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 Feb 25	Sell€3,562	Stuart Poulton	Individual	394.27	€9.03
04 Feb 25	Sell€2,568	Richard Paulson	Individual	273.27	€9.40
06 Jan 25	Sell€3,056	Richard Paulson	Individual	270.33	€11.30
04 Dec 24	Sell€2,784	Richard Paulson	Individual	241.33	€11.54
05 Nov 24	Sell€3,065	Richard Paulson	Individual	245	€12.51
04 Oct 24	Sell€2,893	Richard Paulson	Individual	240.47	€12.03
04 Sep 24	Sell€3,489	Sohanya Cheng	Individual	357.07	€9.77
04 Sep 24	Sell€4,592	Michael Mason	Individual	470	€9.77
04 Sep 24	Sell€2,389	Richard Paulson	Individual	244.47	€9.77
04 Sep 24	Sell€2,587	Michael Mano	Individual	264.73	€9.77
06 Aug 24	Sell€3,069	Richard Paulson	Individual	240.53	€12.76
30 Jul 24	Sell€2,829	Stuart Poulton	Individual	192.2	€14.72
05 Jul 24	Sell€2,842	Richard Paulson	Individual	241.07	€11.79
07 Jun 24	Sell€726,307	Delphi Ventures, LLC	Company	54,536.29	€13.64
04 Jun 24	Sell€809,356	Delphi Ventures, LLC	Company	60,411.9	€13.79
04 Jun 24	Sell€593	Michael Mason	Individual	43.47	€13.65
04 Jun 24	Sell€3,268	Richard Paulson	Individual	239.47	€13.65
06 May 24	Sell€3,750	Richard Paulson	Individual	238.4	€15.73
22 Apr 24	Sell€7,463	Reshma Rangwala	Individual	452.6	€16.49
04 Apr 24	Sell€4,231	Richard Paulson	Individual	237.53	€17.81

Insider Trading Volume

Insider Buying: 25K0 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 25K0?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	51,333	0.61%
Hedge Funds	1,070,982	12.7%
General Public	3,190,600	37.9%
Institutions	4,103,092	48.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 55.71% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
7.72%	Highbridge Capital Management, LLC	649,659	€3.7m	0%	0.61%
6.06%	The Vanguard Group, Inc.	510,299	€2.9m	0%	no data
5.44%	J. Wood Capital Advisors LLC, Asset Management Arm	458,135	€2.6m	0%	no data
5.01%	Adage Capital Management, L.P.	421,323	€2.4m	46.3%	0.01%
3.89%	Palo Alto Investors LP	327,133	€1.9m	-3.83%	0.38%
2.99%	BlackRock, Inc.	251,258	€1.4m	3.59%	no data
2.78%	Morgan Stanley, Investment Banking and Brokerage Investments	234,164	€1.3m	2,770%	no data
2.46%	Citadel Advisors LLC	206,911	€1.2m	0%	no data
1.9%	Marshall Wace LLP	160,094	€907.4k	15.3%	no data
1.85%	Catalio Capital Management, LP	155,625	€882.0k	0%	0.26%
1.65%	Eversept Partners, L.P.	139,250	€789.2k	-62.4%	0.11%
1.6%	Avidity Partners Management, L.P.	134,566	€762.7k	-57.4%	0.1%
1.27%	GSA Capital Partners LLP	106,562	€604.0k	-9.98%	0.06%
1.19%	C WorldWide Asset Management Fondsmaeglerselskab A/S	100,000	€566.8k	0%	0.01%
1.18%	UBS O'Connor LLC	98,915	€560.6k	24%	0.06%
1.1%	Geode Capital Management, LLC	92,820	€526.1k	2.72%	no data
1.06%	Goldman Sachs Group, Investment Banking and Securities Investments	89,051	€504.7k	-0.07%	no data
1.04%	BNP Paribas Arbitrage Sa, Asset Management Arm	87,592	€496.4k	-33.7%	no data
1.01%	Deutsche Asset & Wealth Management	84,585	€479.4k	0%	no data
0.95%	Renaissance Technologies LLC	80,172	€454.4k	-3.13%	no data
0.95%	Kennedy Capital Management LLC	79,686	€451.6k	-0.72%	0.01%
0.91%	Millennium Management LLC	76,960	€436.2k	-8.03%	no data
0.59%	Jane Street Group, LLC, Asset Management Arm	49,887	€282.7k	265%	no data
0.59%	Altium Capital Management LP	49,333	€279.6k	0%	0.12%
0.53%	Susquehanna International Group, LLP, Asset Management Arm	44,276	€250.9k	120%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/06 01:17
End of Day Share Price	2025/02/25 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Karyopharm Therapeutics Inc. is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Peter Lawson	Barclays
Ying Huang	BofA Global Research